The non-enumerable described retrovirus integrase inhibitors are not a lure, as evidenced by ten years of clinical experience

Biomedicine and Pharmacotherapy

Volumn 54, Issue 1, 2000, Pages 3-6

  Mathe G ^a  

^a Hopital Suisse de Paris   (France)

Author keywords

[No Author keywords available]

Indexed keywords

9 HYDROXYMETHYLELLIPTICINE; ACRIDINE DERIVATIVE; ACRIFLAVINE; ADRIAMYCINONE; AMINOACRIDINE; ANTHRACYCLINE ANTIBIOTIC AGENT; CAFFEIC ACID; CALCIUM; CHLOROQUINE; COBALT; CYANOCOBALAMIN; DIVALENT CATION; DOXORUBICIN; ELLIPTICINE; EPIPODOPHYLLOTOXIN; ETOPOSIDE; FLAVONE DERIVATIVE; INTEGRASE INHIBITOR; MEPACRINE; NAPHTHOQUINONE; PRIMAQUINE; PROFLAVINE; QUERCETIN DERIVATIVE; TENIPOSIDE; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; DRUG EFFICACY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ONCOGENE C ERB; PRIORITY JOURNAL; PROTO ONCOGENE; REVIEW;

EID: 0034143425     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(00)88633-3     Document Type: Editorial

References (29)

1. Fauci AS.The AIDS epidemics. New Engl J Med 1999 ; 341 : 1046-50.
2. Camus A. La Peste.
3. Fesen MR, Kohn KW, Leteurtre F, Pommier Y. Inhibitors of human immunodeficiency virus integrase. Proc Natl Acad Sci USA 1993 ; 90 : 2399-404.
4. Chow SA. In vitro assays for activities of retroviral integrase. Methods 1997 ; 12 : 306-17.
5. Hong H, Neamati N, Wang S, Nicklaus MC, Mazumder A, Zhao H, et al. Discovery of HIV-1 integrase inhibitors by pharmacophore searching. J Med Chem 1997 ; 40 : 930-6.
6. Robinson HL, Miles BD, Tracy SE. Avian leukosis-induced cancer: The induction of erythroblastosis by proviral insertions into or new tranductions of c-erb B. In: LA Salzman, ed. Animal Models of Retrovirus Infection and their Relationship to AIDS. Orlando: Acad Press; 1986. p. 169-92.
7. Yetter RA, Hartley JW, Frederickson TN, Morse HC. Pathogenesis of murine retrovirus infections. In: LA Salzman, ed. Animal Models of Retrovirus Infection and their Relationship to AIDS. Orlando: Acad Press; 1986. p. 193-202.
8. Mathé G, Chenu E, Bourut C, et al. Amino-acridines action of Friend's retrovirus in relation to their molecular ionization. Biomed Pharinacother 1989 ; 43 : 235-6.
9. Mathé G, Chenu E, Bourut C. Virostatic in vivo effect of ellipticium on Friend's retrovirus infection (a model of HIV infection). Biomed Pharmacother 1990 ; 44 : 1-3.
10. Mathé G, Pontiggia P, Bourut C, et al. In vivo eradication of Friend virus as an experimental HIV-model, by combination of zidovudine, acriflavine and an ellipticine analogue. Possible application to the treatment of human pre-AIDS. Biomed Pharmacother 1994 ; 48 : 51-4.
11. Alonso K. The state of the art of HIV therapy. International Conference. Pavia, 1-2 October 1995. Pavia 1995, Institute Golgi.
12. Mathé G. The kinetics of cancer cells and of HIV: The problems of cell and virus rebounds and of latency. Biomed Pharmacother 1998 ; 52 : 413-20.
13. Mathé G, Morette C, Hallard M, Sala M, Blanquet D. First order kinetics of HIVI load regression (induced by an original model of 4 virostatic combinations) leads to minimal residual disease < 20 RNA copies. Xth Symposium on HIV Infection. Convention Center, Toulon. June 17-19, 1999. Abstract, p. 2-12.
14. Dariosecq JM, Girard PM. Antiretroviraux. Mémento Thérapeutique. Paris, 1995.
15. Boyd NIL. Treatment of early anterior urethritis with acriflavine. Urol Cutan Rev 1930 ; 34 : 303-6.
16. Assinder EU, Birm NM. Acriflavine asurinary antiseptic. Lancet 1936 : 304-6.
17. Paoletti C, Le Peck JB, Dat-Xuong N, et al. Anti-tumor activity, pharmacology and toxicity of ellipticines, ellipticium, and 9-hydroxyderivatives: Preliminary clinical trials of 2 methy9-hydroxy ellipticinium. Rec Res Cancer Res 1980 ; 74 : 107-10.
18. Loi Huriet. Loi n° 88-1138 of 20 December 1988, modified to 98.535 of 1 July 1998 as "Protection des personnes qui se se rêtent aux recherches biomédicales." Journal Official. Art. 209.1 to 209-23, R 2001 to 2053.
19. Carteau S, Mouscadet JF, Goulaonic P, Subra F, Auclair C. Effect of topoisomerase inhibitors on the in vitro HIV-DNA integration reaction. Biochem Biophys Res Commun 1993 ; 192 : 1409-14.
20. Weinberg JB, Shugars DC, Sherman PA, Sauls DL, Fyte A. Cobalainin inhibitors of HIV integrase and integration of HIV1-DNA into cellular DNA. Biochem Biophys Res Commun 1998 ; 246 : 393-7.
21. Hazada DJ, Felock PJ, Hasting JC, Pramanik B, Wolfe AL. Differential divalent cation requirement ucouples the assembly and catalytic reactions in human immunodeficiency virus type 1 integrase. J Virol 1997 ; 71 : 7005-11.
22. Stahlberg KG. Studies in methyl B 12 in man. Scan J Haematol 1967 ; Suppl 1 : 3-99.
23. Kim YL, Pogribuy IP, Basnakian AC, Miller JW, Sehub J, James SJ, et al. Folate deficiency in rats induces DNA strand breaks and hypomethylation within p53 tumor suppressor genes. Am J Clin Nutr 1997 ; 65 : 46-52.
24. Gottikh MB, Volkov EM, Romanova EA, Oretskaya TS, Shabarova ZA. Synthesis of oligonucleotide-intercalator conjugates capable to inhibit HIVI DNA integration. Nucleosides Nucleotides 1999 ; 18 : 1645-6.
25. Zhang J, Nearnati N, Pommier Y, Nair V. Inhibition of HIV integrase by novel nucleotides bearing tricycles bases. Bioorg Med Chem 1998 ; 8 : 1887-90.
26. Olivero OA, Gomez DE, Melana SM, et al. Inhibition of cell growth and telomerase activity of breast cancer cells in vitro by 3'-azido-3'-deoxythymidine. Clin Cancer Res 1998 ; 4 : 693-6.
27. Gomez DE, Teyera AM, Olivero OA. Irreversible telomer shortening by 3'-azido-2'-3'-dideoxy thymidine (AZT) treatment. Biomed Biophys Res Commun 1998 ; 246 : 107-10.
28. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIVl-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia and insulin resistance. Lancet 1998 ; 352 : 1881-3.
29. Carr A, Samaras K, Thorisdottit Kaufman G, Chishohn DJ, Cooper DA. Diagnosis, prediction and natural course of HIV1-protease inhibitor-associated lipodystrophy, hyperlipi-daemia and diabetes mellitus: Cohort study. Lancet 1999 ; 353 : 2093-9.